Feline Cell, Per Se Patents (Class 435/351)
  • Publication number: 20150141289
    Abstract: The invention provides for compositions and methods for identifying and validating modulators of cell fate, such as such as maintenance, cell specification, cell determination, induction of stem cell fate, cell differentiation, cell dedifferentiation, and cell trans-differentiation. The invention relates to reporter nucleic acid constructs, host cells comprising such constructs, and methods using such cells and constructs. The invention relates to methods for making cells comprising one or more reporter nucleic acid constructs using fluorogenic oligonucleotides. The methods relate to high throughput screens.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Inventors: Kambiz Shekdar, Dennis J. Sawchuk, Jessica C. Langer
  • Publication number: 20150132845
    Abstract: Devices, systems, and methods for continuous cell culture and other reactions are generally described. In some embodiments, chambers (e.g., cell growth chambers) including at least a portion of a wall formed of a flexible member are provided. A retaining structure can be incorporated outside and proximate to the chamber such that when liquid is added to the chamber, the flexible member is consistently and predictably deformed, and a consistent volume of liquid is added. The flexible member can be formed of, in some embodiments, a gas-permeable medium. In some embodiments, reaction chambers can be arranged in a fluidic loop, and a bypass channel can be used to introduce and/or extract fluid from the loop without affecting loop operation.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 14, 2015
    Applicant: Massachusetts Institute of Technology
    Inventors: Rajeev Jagga Ram, Kevin Shao-Kwan Lee
  • Publication number: 20150132853
    Abstract: Methods for de-differentiating or altering the life-span of desired “recipient” cells, e.g., human somatic cells, by the introduction of cytoplasm from a more primitive, less differentiated cell type, e.g., oocyte or blastomere are provided. These methods can be used to produce embryonic stem cells and to increase the efficiency of gene therapy by allowing for desired cells to be subjected to multiple genetic modifications without becoming senescent. Such cytoplasm may be fractionated and/or subjected to subtractive hybridization and the active materials (sufficient for de-differentiation) identified and produced by recombinant methods.
    Type: Application
    Filed: June 11, 2014
    Publication date: May 14, 2015
    Applicant: Advanced Cell Technology, Inc.
    Inventor: Karen B. Chapman
  • Publication number: 20150065560
    Abstract: The present invention relates to a one-vector expression system comprising a sequence encoding two polypeptides, such as tyrosine hydroxylase (TH) and GTP-cyclohydrolase 1 (GCH1). The two polypeptides can be should preferentially be expressed at a ratio between 3:1 and 15:1, such as between 3:1 and 7:1. The invention is useful in the treatment of catecholamine deficient disorders, such as dopamine deficient disorders including but not limited to Parkinson's Disease. Moreover, the present invention provides a method to deliver the vector construct in order to limit the increased production of the catecholamine to the cells in need thereof.
    Type: Application
    Filed: April 1, 2014
    Publication date: March 5, 2015
    Inventors: Tomas Björklund, Anders Björklund, Deniz Kirik
  • Publication number: 20150064148
    Abstract: The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject STRO-1+ cells and/or progeny cells thereof and/or soluble factors derived therefrom. The method of the invention is useful for treating and/or preventing and/or delaying the onset or progression of a disorder resulting from or associated with pancreatic dysfunction, e.g., resulting from abnormal endocrine or exocrine function of the pancreas.
    Type: Application
    Filed: November 7, 2014
    Publication date: March 5, 2015
    Applicant: MESOBLAST, INC.
    Inventors: Silviu Itescu, Ravi Krishnan
  • Publication number: 20150050298
    Abstract: A method for suppressing an immune response is provided. The method involves administration of isolated lymphoid tissue-derived suppressive stromal cells (LSSC) to a subject in need of such treatment in an amount effective to suppress the immune response in the subject. The invention also involves a method to isolate LSSC by digesting lymphoid tissue fragments using a combination of an enzyme mix and agitation and then collecting the LSSC. Pharmaceutical preparations comprising LSSC are also provided.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 19, 2015
    Inventors: Anne Fletcher, Shannon J. Turley, Biju Parekkadan
  • Publication number: 20150044772
    Abstract: An inactive CRISPR/Cas system-based fusion protein and its applications in gene editing are disclosed. More particularly, chimeric fusion proteins including an inCas fused to a DNA modifying enzyme and methods of using the chimeric fusion proteins in gene editing are disclosed. The methods can be used to induce double-strand breaks and single-strand nicks in target DNAs, to generate gene disruptions, deletions, point mutations, gene replacements, insertions, inversions and other modifications of a genomic DNA within cells and organisms.
    Type: Application
    Filed: August 8, 2014
    Publication date: February 12, 2015
    Inventor: Guojun Zhao
  • Publication number: 20150017138
    Abstract: Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating an inflammatory disease or disorder. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 15, 2015
    Inventors: Johannes H. Fruehauf, Chiang J. Li
  • Publication number: 20150005369
    Abstract: Disclosed are methods of gene delivery using capsid-modified recombinant adeno-associated viral (rAAV) vectors. Exemplary methods are provided employing vectors that have altered affinity for heparin or heparin sulfate, as well as vectors, expression systems, and rAAV virions that lack functional VP2 protein expression, but are nevertheless, fully virulent. Also provided by the invention are methods employing the rAAV vector-based compositions, virus particles, host cells, and pharmaceutical formulations in the expression of selected therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in selected mammals, including organs, tissues, and human host cells.
    Type: Application
    Filed: July 8, 2014
    Publication date: January 1, 2015
    Inventors: Nicholas Muzyczka, Shaun R. Opie, Kenneth H. Warrington
  • Publication number: 20140377296
    Abstract: The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.
    Type: Application
    Filed: April 17, 2014
    Publication date: December 25, 2014
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Christopher W. Olsen, Gabriele A. Landolt, Alexander I. Karasin
  • Patent number: 8900860
    Abstract: The present invention relates to a novel method for expanding mesenchymal stem cells (MSCs) in low-density and hypoxic condition as compared to normal air conditions traditionally used in cell culture. The present method provides rapid and efficient expansion of human MSCs without losing cellular proliferation and stem cell properties, including increase in proliferation, decrease in senescence, and increase in differentiation potential both in vitro and in vivo. The expanded MSCs by the present method may maintain normal karyotyping, and will not form tumor when transplanted into mammal.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: December 2, 2014
    Assignee: National Yang-Ming University
    Inventor: Shih-Chieh Hung
  • Publication number: 20140322812
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Application
    Filed: April 24, 2014
    Publication date: October 30, 2014
    Applicant: Intrexon Corporation
    Inventors: Subba Reddy PALLI, Mohan Basavaraju KUMAR
  • Publication number: 20140308247
    Abstract: This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing one or more proteins under the control of a gene expression modulation, system in the presence of activating ligand and uses for therapeutic purposes in animals. The vector may be provided to treat or prevent disease.
    Type: Application
    Filed: March 2, 2012
    Publication date: October 16, 2014
    Applicant: Intrexon Corporation
    Inventors: Jeremiah F. Roeth, Brandon Cuthbertson, Charles C. Reed, Sunil Chada, William E. Fogler, Fayas Khazi
  • Publication number: 20140273001
    Abstract: A family of novel feline bitter taste receptors, referred to as feline TAS2R (fTAS2R), are disclosed herein. Isolated polynucleotides encoding the novel feline bitter taste receptors and chimeric polypeptides are also disclosed, as are expression vectors and host cells for expression of the novel feline bitter taste receptors. Methods of identifying compounds that bind to the novel feline bitter taste receptors and modulate their activity are disclosed.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 18, 2014
    Applicant: AFB International
    Inventors: Michelle M. Sandau, Nancy E. Rawson
  • Publication number: 20140208457
    Abstract: The present invention is concerned with nuclease fusion proteins and various uses thereof. Specifically, it relates to a polynucleotide encoding a polypeptide comprising (i) a first module comprising at least a first DNA binding domain derived from a homing endonuclease, (ii) a linker, and (iii) a second module comprising at least a second DNA binding domain and a cleavage domain derived from a restriction endonuclease, wherein said polypeptide functionally interacts only with DNA comprising a DNA recognition site for the first DNA binding domain and a DNA recognition site for the second DNA binding domain, and wherein said cleavage domain cleaves DNA within a specific DNA cleavage site upon binding of the polypeptide. Further contemplated are a vector and a non-human transgenic organism comprising said polynucleotide as well as a polypeptide encoded by the polynucleotide of the invention.
    Type: Application
    Filed: June 8, 2012
    Publication date: July 24, 2014
    Applicant: BASF PLANT SCIENCE COMPANY GMBH
    Inventors: Ines Fonfara, Wolfgang Wende, Alfred Pingoud
  • Publication number: 20140186395
    Abstract: Described are methods for determining the permissiveness of a cell for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular, for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). Further described are methods and compositions related to the generation of host cells permissive for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular, for PRRSV. Methods of utilzing the cells thus identified or thus generated, in preparing a culture of a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, as well as the use of the virus for the purpose of vaccine production or diagnosis, are also described.
    Type: Application
    Filed: March 13, 2013
    Publication date: July 3, 2014
    Applicant: Universiteit Gent
    Inventors: Peter Delputte, Hans Nauwynck, Hanne Van Gorp
  • Publication number: 20140170746
    Abstract: Provided is a method of dedifferentiating somatic cells using embryonic stem cell-derived microvesicles. Particularly, a method of preparing induced pluripotent stem cells by treating a composition including embryonic stem cell-derived microvesicles to the somatic cells. According to the method of preparing induced pluripotent stem cells, the dedifferentiation of the somatic cells may be efficiently performed without side effects using the embryonic stem cell-derived microvesicles, and moreover, the method is expected to be very useful in developing a cell therapy product having immunocompatibilities by individuals.
    Type: Application
    Filed: April 19, 2012
    Publication date: June 19, 2014
    Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Jae-Sung Park, Yong Song Gho, Yoon Keun Kim, Jun Ho Kim, Su Chul Jang, Namwoo Yi, Dayeong Jeong, Eun-Jeong Choi
  • Patent number: 8728808
    Abstract: The present invention relates to the field of biotechnology or genetic engineering. More specifically, the present invention relates to a multiple inducible gene regulation system that functions within cells to simultaneously control the quantitative expression of multiple genes.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: May 20, 2014
    Assignee: Intrexon Corporation
    Inventors: Tarlochan Singh Dhadialla, Dean Ervin Cress, Glenn Richard Carlson, Robert Eugene Hormann, Subba Reddy Palli, Arthur John Kudla, Ronald Phillip Herzig, Jr., Mohan Philip
  • Publication number: 20140134723
    Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.
    Type: Application
    Filed: October 28, 2013
    Publication date: May 15, 2014
    Applicant: Sangamo BioSciences, Inc.
    Inventors: Philip D. Gregory, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Siyuan Tan, Fyodor Urnov, Lei Zhang
  • Publication number: 20140134739
    Abstract: A transgenic cat with a phenotype characterized by the substantial absence of the major cat allergen, Fel d I. The phenotype is conferred in the transgenic cat by disrupting the coding sequence of the target gene with a specialized construct. The phenotype of the transgenic cat is transmissible to its offspring.
    Type: Application
    Filed: January 22, 2013
    Publication date: May 15, 2014
    Inventor: David B. AVNER
  • Publication number: 20140134740
    Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.
    Type: Application
    Filed: October 28, 2013
    Publication date: May 15, 2014
    Applicant: Sangamo BioSciences, Inc.
    Inventors: Philip D. Gregory, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Siyuan Tan, Fyodor Urnov, Lei Zhang
  • Publication number: 20140065110
    Abstract: This disclosure relates to vectors, isolated cells, compositions, and methods for the treatment of critical limb ischemia and associated disorders. One aspect of the disclosure relates to a vector comprising a nucleic acid encoding a 165A isoform VEGF protein and a promoter that regulates expression of the nucleic acid encoding the VEGF.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 6, 2014
    Applicant: The Regents of the University of California
    Inventors: Jan Nolta, Karen Pepper, Fernando Fierro, Gerhard Bauer
  • Publication number: 20140023723
    Abstract: Methods for producing compositions of decellularized extracellular matrix (DM) tissue culture are described. The compositions can be used for coating supports such as tissue culture substrates, osteogenic gels, and medical devices.
    Type: Application
    Filed: April 16, 2012
    Publication date: January 23, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: J. Kent Leach, Martin Decaris, Archana Bhat
  • Publication number: 20140018385
    Abstract: Pharmaceutical compositions and methods for inhibiting cell growth, modulating function of PCNA, treating prostate cancer, and enhancing PCNA trimer formation are disclosed.
    Type: Application
    Filed: September 8, 2011
    Publication date: January 16, 2014
    Applicant: UNIVERSITY OF CINCINNATI
    Inventors: Zhongyun Dong, Matthew Wortman, Zonqing Tan, Kelsey Dillehay
  • Publication number: 20130337431
    Abstract: Generally, compositions and methods for handling processed sperm populations including samples that are freshly collected, transported as fresh samples, as well as samples that are frozen and thawed, those sorted into one or more subpopulations, and those that are otherwise processed or handled that impose trauma on the sperm cell. Such trauma can reduce the motility, fertility, viability and overall integrity of the sperm and reduce the sperm's ability to fertilize an egg, grow into a healthy embryo and produce a healthy offspring. The novel compounds described can be added to the sperm cell sample to reduce the traumatic effects of physical stress during mild as well as extensive sperm cell processing, methods of using the compounds in standard sperm processing procedures, the end products made from these methods including sperm and embryos, as well as methods of using those end products in assisted reproductive biology techniques in animals.
    Type: Application
    Filed: March 15, 2013
    Publication date: December 19, 2013
    Applicant: INGURAN, LLC
    Inventor: INGURAN, LLC
  • Publication number: 20130330358
    Abstract: Two vIRF4 (Kaposi's-sarcoma-associated-herpesvirus vIRF4) peptides, vif1, corresponding to aa202-216 of vIRF4, and vif2, corresponding to aa220-236 of vIRF4, are potent and selective HAUSP antagonists. The vif1 and vif2 peptides robustly suppress HAUSP DUB enzymatic activity, ultimately leading to p53-mediated anti-cancer activity. The vif1 and vif2 peptides, along with their homologues, are useful in treating cancer through regulation of p53 activity in a cancer cell. Also disclosed is the crystalline structure of vIRF4-HAUSP TRAF domain complex. The structure is useful in computer aided drug design for identifying an agent that interacts with and inhibits HAUSP, resulting in p53 medicated cell cycle arrest of cancer cells.
    Type: Application
    Filed: February 22, 2012
    Publication date: December 12, 2013
    Inventors: Jae Jung, Hye-Ra Lee, Myung Hee Kim, Tae-Kwang Oh, Jung-Won Hwang
  • Publication number: 20130305397
    Abstract: This invention relates to a cell comprising a reporter gene under control of an ARIA gene promoter, the cell being used for searching for an agent for prevention or treatment of diseases attributed to reduced insulin sensitivity, for searching for an obesity-controlling substance, or for searching for an obesity-inducing substance.
    Type: Application
    Filed: January 20, 2012
    Publication date: November 14, 2013
    Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
    Inventors: Koji Ikeda, Hiroaki Matsubara, Yoshiki Akakabe
  • Publication number: 20130280801
    Abstract: Disclosed herein are flowable tissue matrix compositions comprising small pieces of partially or completely decellularized tissue suspended in a gelatinized tissue or gelatin gel comprising partially or completely decellularized tissue or synthetic gelatin. The flowable tissue matrix compositions can contain factors that promote or enhance native cell migration, proliferation, and/or revascularization after implantation into a subject. Also disclosed are methods of making and using the flowable tissue matrix compositions. The compositions can be implanted into a tissue in need of repair, regeneration, healing, treatment, and/or alteration, and can promote or enhance native cell migration, proliferation, and/or revascularization.
    Type: Application
    Filed: April 23, 2013
    Publication date: October 24, 2013
    Applicant: LifeCell Corporation
    Inventor: Wenquan Sun
  • Publication number: 20130259884
    Abstract: The application discloses peptides capable of preventing or treating fungal disease, including fungal allergy disease.
    Type: Application
    Filed: September 23, 2011
    Publication date: October 3, 2013
    Applicant: ALERGENETICA SL
    Inventors: Nigel Stuart Dunn-Coleman, Maria R. Diaz-Torres, Brian Miller
  • Publication number: 20130236931
    Abstract: An in vitro system for generating sequence, and thus structural, diversity in proteins is described. The system can be constructed using appropriately selected nucleic acid molecules that encode regions of a selected protein or proteins and recombination signal sequences (RSS). The selected protein(s) can be, for example, immunoglobulin (Ig) V, D, J and/or C regions, regions of a non-immunoglobulin (non-Ig) protein, or a combination of Ig regions and non-Ig regions. Assembly of such appropriately selected components and their introduction into suitable recombination-competent host cells allows for recombination between the RSS sequences and introduction of sequence and structural diversity into the protein(s).
    Type: Application
    Filed: February 12, 2013
    Publication date: September 12, 2013
    Inventors: Michael Gallo, Jaspal Singh Kang, Craig Robin Pigott
  • Publication number: 20130196430
    Abstract: The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport.
    Type: Application
    Filed: June 12, 2012
    Publication date: August 1, 2013
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Hitto KAUFMANN, Lore FLORIN, Eric BECKER, Monilola OLAYIOYE, Angelika HAUSSER, Tim FUGMANN
  • Publication number: 20130183656
    Abstract: The present invention relates to compositions and methods for the handling of processed sperm including samples that are freshly collected, those transported as fresh samples, samples that are frozen and thawed, those sorted into one or more subpopulations, and those that are otherwise processed or handled that impose trauma on the cell. Trauma can reduce the motility, fertility, viability and overall integrity of the sperm and reduce the ability to fertilize, produce an embryo and a healthy offspring. The present invention relates to novel compounds that can be added to the sperm cell sample to reduce the traumatic effects of physical stress during mild as well as extensive sperm cell processing, methods of using the compounds in standard sperm processing procedures, the end products made from these methods including sperm and embryos, as well as methods of using those end products in assisted reproductive biology techniques in animals.
    Type: Application
    Filed: June 1, 2012
    Publication date: July 18, 2013
    Applicant: INGURAN, LLC
    Inventors: Richard Lenz, Juan Moreno, Ramakrishnan Vishwanath
  • Publication number: 20130130374
    Abstract: Methods for preparing a variety of cell (e.g., hepatocyte) preparations and preparations so prepared are described. Uses of such preparations are described. In one embodiment, centrifugal elutriation is used to separate hepatocytes with preferred characteristics. Such hepatocyte preparations may be used for cryopreservation, multiple cryopreservations, in vitro assays, plating and other methods for which preparations of hepatocytes are useful.
    Type: Application
    Filed: August 3, 2011
    Publication date: May 23, 2013
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Mark Powers, Rafal Witek, Kirsten Amaral
  • Publication number: 20130117872
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Application
    Filed: September 14, 2012
    Publication date: May 9, 2013
    Inventors: Subba Reddy PALLI, Mohan Basavaraju Kumar, Dean Ervin Cress, Ted Tsutomu Fujimoto
  • Publication number: 20130104253
    Abstract: Methods for de-differentiating or altering the life-span of desired “recipient” cells, e.g., human somatic cells, by the introduction of cytoplasm from a more primitive, less differentiated cell type, e.g., oocyte or blastomere are provided. These methods can be used to produce embryonic stem cells and to increase the efficiency of gene therapy by allowing for desired cells to be subjected to multiple genetic modifications without becoming senescent. Such cytoplasm may be fractionated and/or subjected to subtractive hybridization and the active materials (sufficient for de-differentiation) identified and produced by recombinant methods.
    Type: Application
    Filed: September 14, 2012
    Publication date: April 25, 2013
    Inventor: Karen B. CHAPMAN
  • Patent number: 8415151
    Abstract: This invention provides a crystalline recombinant interferon (rSIFN-co (SEQ ID NO: 1)) having (i) the same amino acid sequence as that of human consensus interferon, and (ii) altered three-dimensional structure as compared to IFN-?2b. The interferon of the present invention exhibits enhanced biological activities. The present invention also provides a structure model of said interferon useful for drug screening and/or drug design and the mimetic of said interferon.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: April 9, 2013
    Inventors: Guangwen Wei, Dacheng Wang
  • Publication number: 20130078718
    Abstract: Disclosed herein is a method of producing multipotent cells, comprising, activating ALK2 of isolated endothelial cells in a serum starved environment, to thereby produce isolated multipotent cells. Activation can be following a threshold period of serum starvation. Activating ALK2 is by contacting the isolated endothelial cells with TGF?-2 and/or BMP4. The isolated endothelial cells may be human, such as primary vascular, primary microvascular endothelial cells, primary human umbilical vein endothelial cells (HUVEC) or primary human cutaneous microvascular endothelial cells (HCMEC). The activation of ALK2 significantly decreases expression of VE-cadherein of the cells and/or significantly increases expression of one or more of STRO-1, FSP-1, ?-SMA, N-cadherin, fibronectin (FN1), Snail (SNAI1), Slug (SNAI2), ZEB-1, SIP-1, LEF-1, Twist, CD10, CD13, CD44, CD73, CD90, CD120A, and CD124.
    Type: Application
    Filed: March 9, 2011
    Publication date: March 28, 2013
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Damian Medici, Bjorn Olsen
  • Publication number: 20130074218
    Abstract: The present invention discloses a method for modulating the quality of a selected phenotype that is displayed by an organism or part thereof and that results from the expression of a polypeptide-encoding polynucleotide by replacing at least one codon of that polynucleotide with a synonymous codon that has a higher or lower preference of usage by the organism or part thereof to produce the selected phenotype than the codon it replaces. The present invention is also directed to the use of a codon-modified polynucleotide so constructed for modulating the quality of a selected phenotype displayed by an organism or part thereof.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 21, 2013
    Applicant: The University of Queensland
    Inventor: Ian Hector FRAZER
  • Publication number: 20130052728
    Abstract: The invention provides compositions for making erythroid progenitor cells that comprise in vitro-activated bone marrow mesenchymal stem cells and embryoid bodies (EBs) or pluripotent stem cells, and methods for making and using them, including ameliorating (e.g., preventing or treating) anemia and/or stimulating erythropoiesis. In one embodiment, the invention provides methods of increasing propensity of committed stem cell differentiation towards the erythroid lineage.
    Type: Application
    Filed: November 30, 2010
    Publication date: February 28, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Ewa Carrier
  • Publication number: 20130017547
    Abstract: The present invention relates to isolated organ-specific feline endothelial cells. Specifically, the present invention relates to established organ-specific feline endothelial cells. The present invention also relates to organ-specific feline endothelial cells derived from micro- and macro-vascularisation. The present invention also relates to methods for screening molecules, for studying pathologies and for producing pathogens using same.
    Type: Application
    Filed: January 11, 2011
    Publication date: January 17, 2013
    Applicants: ECOLE NATIONALE VETERINAIRE D'ALFORT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE - CNRS
    Inventors: Claudine Kieda, Maria Paprocka, Michele Mitterand, Nathalie Lamerant-Fayel, Henri-Jean Boulouis, Nadia Haddad, Martine Monteil
  • Publication number: 20120329151
    Abstract: An apparatus and method to maintain pH within a range conducive for cell growth in a bicarbonate-containing cell culture system without the addition of base. The method relies on the gas transfer characteristics of the bioreactor system to modulate the CO2 transfer to and from the cell culture such that the pH of the cell culture can be maintained within a desired range.
    Type: Application
    Filed: July 6, 2010
    Publication date: December 27, 2012
    Applicant: F. HOFFMANN-LA ROCHE AG
    Inventors: Dinesh Baskar, Jenny Hsiung, Woon-Lam Susan Laung, Inn H. Yuk
  • Publication number: 20120322148
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic plants and animals.
    Type: Application
    Filed: May 3, 2012
    Publication date: December 20, 2012
    Applicant: Intrexon Corporation
    Inventors: Subba Reddy Palli, Marianna Zinovjevna Kapitskaya, Dean Ervin Cress
  • Publication number: 20120316114
    Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
    Type: Application
    Filed: May 8, 2012
    Publication date: December 13, 2012
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel C. Vellard, Augustus O. Okhamafe
  • Publication number: 20120282305
    Abstract: Biological surfactants connected to surfaces of silicone-based materials are provided. Compositions of electrolytes and a biological surfactant are also provided. Methods for increasing the surface wettability of a silicone-based material by contacting the silicone-based material with a biological surfactant, methods for increasing evaporation from a silicone-based material by contacting a surface of the silicone-based material with a biological surfactant, methods for increasing levels of interleukin-8 during inflammation by contacting a cell with a biological surfactant, and methods for decreasing expression of a biological surfactant by contacting a cell with an siRNA are further provided.
    Type: Application
    Filed: January 7, 2011
    Publication date: November 8, 2012
    Applicant: The Research Foundation of State University of New York
    Inventors: Xiaolan Lin, Miriam Rafailovich
  • Publication number: 20120283136
    Abstract: This invention provides new combinatorial approaches for the biosynthesis and screening of cyclic peptides inside living cells. These novel approaches are useful for finding biologically relevant molecules, e.g., those able to inhibit the cytotoxicity of Anthrax Edema Factor. Key to this ‘living combinatorial’ approach is the use of a living cell as a micro-chemical factory for both synthesis and screening of potential inhibitors for a given molecular recognition event.
    Type: Application
    Filed: June 23, 2010
    Publication date: November 8, 2012
    Inventor: Julio A. Camarero
  • Publication number: 20120276572
    Abstract: The invention provides for compositions and methods for identifying and validating modulators of cell fate, such as such as maintenance, cell specification, cell determination, induction of stem cell fate, cell differentiation, cell dedifferentiation, and cell trans-differentiation. The invention relates to reporter nucleic acid constructs, host cells comprising such constructs, and methods using such cells and constructs. The invention relates to methods for making cells comprising one or more reporter nucleic acid constructs using fluorogenic oligonucleotides. The methods relate to high throughput screens.
    Type: Application
    Filed: July 30, 2010
    Publication date: November 1, 2012
    Applicant: CHROMOCELL CORPORATION
    Inventors: Kambiz Shekdar, Dennis J. Sawchuk, Jessica C. Langer
  • Publication number: 20120276203
    Abstract: The invention relates to the use of an active collagen matrix for culturing mammalian cells and the use of the active collagen matrix and cells for the treatment of disease.
    Type: Application
    Filed: April 28, 2011
    Publication date: November 1, 2012
    Applicant: WARSAW ORTHOPEDIC, INC.
    Inventors: Abdulhafez A. Selim, Lawrence A. Shimp, Hsiu Ying Sherry Wang
  • Publication number: 20120252117
    Abstract: The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.
    Type: Application
    Filed: April 12, 2011
    Publication date: October 4, 2012
    Inventors: Richard F Selden, Allan M. Miller, Douglas A. Treco
  • Publication number: 20120244131
    Abstract: A method for modulating double-strand break-induced mutagenesis at a genomic locus of interest in a cell, thereby giving new tools for genome engineering, including therapeutic applications and cell line engineering. A method for modulating double-strand break-induced mutagenesis, concerns the identification of effectors that modulate double-strand break-induced mutagenesis by use of interfering agents; these agents are capable of modulating double-strand break-induced mutagenesis through their respective direct or indirect actions on said effectors. Methods of using these effectors, interfering agents and derivatives, respectively, by introducing them into a cell in order to modulate and more particularly to increase double-strand break-induced mutagenesis. Specific derivatives of identified effectors and interfering agents, vectors encoding them, compositions and kits comprising such derivatives for modulating or increasing double-strand break-induced mutagenesis.
    Type: Application
    Filed: February 6, 2012
    Publication date: September 27, 2012
    Applicant: CELLECTIS SA
    Inventors: Fabien Delacote, Philippe Duchateau, Christophe Perez-Michaut
  • Publication number: 20120233717
    Abstract: A method for preparing a transgenic animal of simultaneous multiple-gene expression is provided. Additionally, a method for preparing a transgenic embryo, which introduces both phytase gene and human myxovirus resistant gene A into a target embryo, to obtain a transgenic embryo is provided. The transgenic animal of simultaneous multiple-gene expression can be achieved by transplanting the transgenic embryo into the body of a female target animal. A significant advantage of the foregoing methods, among many others, exists in that the simultaneous expression of multiple genes can be achieved in one transgenosis, which provides a convenient mean for the preparation of combined-gene transferred animals etc.
    Type: Application
    Filed: June 24, 2010
    Publication date: September 13, 2012
    Applicant: Institute of Animal Science, Chinese Academy of Agricultural Sciences
    Inventors: Kui Li, Huiming Ju, Junhua Fan, Lijing Bai, Yulian Mu, Shulin Yang, Zhonglin Tang, Wentao Cui